Moslehi Mohsen, Namdar Fatemeh, Esmaeilifallah Mahsa, Iraji Fariba, Vakili Bahareh, Sokhanvari Fatemeh, Hosseini Seyed-Mohsen, Khamesipour Faham, Sebghatollahi Zahra, Hejazi Sayed-Hossein
Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan.
AIMS Microbiol. 2020 Jun 2;6(2):152-161. doi: 10.3934/microbiol.2020010. eCollection 2020.
Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the genus. In this study, the CL model of Balb/c mice was produced by injection of the cultured metacyclic form of parasite at the base of the tail. The possible recovery of CL ulcers and determination of the optimum dose of imatinib against amastigotes were evaluated. A significant decrease was observed in mice treated with amphotericin B (positive control group) as well as imatinib 50 mg/kg compared to the unreceived drug, negative control group (P<0.05). This study could be promising in gaining insight into the potential of imatinib as an effective treatment approach against CL.
利什曼病作为一种热带和亚热带疾病，在全球90多个国家呈地方性流行。如今，每年影响超过150万人的皮肤利什曼病（CL）缺乏一种确切的治疗方法。伊马替尼是一种抗癌药物，因其酪氨酸激酶抑制剂可抑制Bcr-Abl的异常功能，鉴于蛋白激酶是该属中的关键酶，所以对该药物进行CL治疗测试。在本研究中，通过在Balb/c小鼠尾部基部注射培养的寄生虫后循环体形式建立CL模型。评估了CL溃疡的可能恢复情况以及伊马替尼针对无鞭毛体的最佳剂量。与未接受药物的阴性对照组相比，用两性霉素B（阳性对照组）以及50 mg/kg伊马替尼治疗的小鼠有显著下降（P<0.05）。这项研究有望深入了解伊马替尼作为CL有效治疗方法的潜力。
